Avalo Therapeutics, Inc. (AVTX) Stock

Avalo Therapeutics, Inc. (AVTX) is a Healthcare stock trading at $14.71 (as of 2026-06-18), with a market capitalization of $722.25M and a trailing P/E of -2.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Avalo Therapeutics, Inc. develops and commercializes targeted therapies for immunology, immuno-oncology, and rare genetic diseases. Its clinical pipeline includes AVTX-002 for conditions such as non-eosinophilic asthma, inflammatory bowel disease, and COVID-19 acute respiratory distress syndrome; AVTX-007 for Still’s disease; and substrate replacement therapies AVTX-801 and AVTX-803 for PGM1-CDG and SLC35C1-CDG.

Valuation — source: SEC EDGAR (first-party)
Price	$14.71
Market Cap	$722.25M
P/E Ratio	-2.8
EV / EBITDA	-9.9
Price / Book	11.85
Price / Sales	13720.50
DCF Value (model)	$-37.73
DCF Upside vs Price	-356.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$59000.00
Net Margin	-132642.4%
Return on Equity	-124.0%
Current Ratio	7.66
Revenue Growth (YoY)	-86.6%
EPS Growth (YoY)	-26.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.49 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.8
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-113.2%
vs Industry	-116.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($42.99M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Garry A. Neil
Employees	23
Country	US
IPO Date	2015-10-14

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.